Home Blog of Signal Transduction Epigenetics PRMT

Category

Archives

Popular Post

ESKM, a novel therapeutic agent for sensitive and resistant PH+ leukemias

The mechanism of resistance to JAK2 inhibitor in myeloproliferative neoplasms patients

Effects of PARP inhibitors in BRCA gene-mutated ovarian cancer

DASATINIB; An inhibitor of Receptor Tyrosine Kinase

GP130/JAK/STAT3 signaling pathway induces multiple myeloma

PRMT

MRTX1719 Is an MTA-Cooperative PRMT5 Inhibitor That Exhibits Synthetic Lethality in Preclinical Models and Patients with MTAP-Deleted Cancer

180 views | Jan 24 2024

MRTX1719, a selective PRMT5 inhibitor, displays remarkable efficacy against MTAP-deleted cancers while sparing MTAP wild-type cells, showcasing promising therapeutic potential and early clinical success across a spectrum of malignancies. [Read the Full Post]

Medicare's Hospital Readmission Reduction Program reduced fall-related health care use: An unexpected benefit?

97 views | Dec 21 2023

The study found that Medicare's Hospital Readmissions Reduction Program (HRRP) was associated with significant reductions in severe fall-related injuries, particularly for congestive heart failure and pneumonia patients, indicating potential improvements in transitional care and post-acute referral patterns. [Read the Full Post]

PRMT3 drives glioblastoma progression by enhancing HIF1A and glycolytic metabolism

158 views | Oct 11 2023

PRMT3 promotes the progression of glioblastoma by enhancing HIF1α-mediated glycolysis and metabolic rewiring, presenting a potential therapeutic target for treating malignant gliomas. [Read the Full Post]

[LLY-283 inhibits proliferation and metastasis of head and neck squamous cell carcinoma by targeting PRMT5]

152 views | Sep 05 2023

LLY-283, by inhibiting PRMT5 expression, effectively suppresses the proliferation and metastasis of Head and Neck Squamous Cell Carcinoma (HNSCC) and reduces tumor growth in vivo. [Read the Full Post]

Phase 1 study of GSK3368715, a type I PRMT inhibitor, in patients with advanced solid tumors

131 views | Sep 03 2023

The Phase 1 study of GSK3368715, a reversible inhibitor of type I protein methyltransferases, was terminated early due to a higher-than-expected incidence of thromboembolic events, limited target engagement at lower doses, and lack of observed clinical efficacy. [Read the Full Post]

Anti-tumor Activity of the Type I PRMT Inhibitor, GSK3368715, Synergizes with PRMT5 Inhibition through MTAP Loss

144 views | Sep 03 2023

GSK3368715, a potent type I PRMT inhibitor, demonstrates anti-tumor effects and its combination with PRMT5 inhibition and consideration of MTAP status as a biomarker strategy show promise for effective oncology treatment. [Read the Full Post]

JNJ-64619178 radiosensitizes and suppresses fractionated ionizing radiation-induced neuroendocrine differentiation (NED) in prostate cancer

245 views | Aug 15 2023

The study demonstrates that JNJ-64619178 inhibits DNA damage repair, radiosensitizes prostate cancer cells, and suppresses FIR-induced neuroendocrine differentiation, suggesting its potential as a therapeutic agent for enhancing the effectiveness of radiation therapy in prostate cancer treatment. [Read the Full Post]

Prmt1 upregulated by Hdc deficiency aggravates acute myocardial infarction via NETosis

125 views | Jul 18 2023

The study reveals that histidine decarboxylase deficiency in mice leads to disorderly recruitment of neutrophils, enhanced migration and ROS/NETs production, promoting cardiac damage, but treatment with histamine or PRMT1 inhibitors attenuates these effects, suggesting potential therapeutic strategies for cardiovascular disease. [Read the Full Post]

TP53 mutations and RNA-binding protein MUSASHI-2 drive resistance to PRMT5-targeted therapy in B-cell lymphoma

244 views | Jul 18 2023

The proposed therapeutic strategy in lymphoma combines PRMT5 inhibition with either MSI2 or BCL-2 inhibition, leveraging the synergistic effects observed to potentially enhance therapeutic efficacy. [Read the Full Post]

PRMT6-CDC20 facilitates glioblastoma progression via the degradation of CDKN1B

168 views | Jul 01 2023

PRMT6, an overexpressed arginine methyltransferase in glioma/GBM, promotes cell proliferation and progression by destabilizing CDKN1B through CDC20-mediated degradation, suggesting potential therapeutic targeting of the PRMT6-CDC20-CDKN1B axis in GBM. [Read the Full Post]